Microplastics and Misinformation: What Science Really Says
November 12, 2025
Brand Name :
No Data Available.
Synonyms :
senna
Class :
Laxative
Liquid of 8.8 mg/5 ml:
10 - 15
ml
Orally
once a day
Maximum dose: 30 ml orally once a day
5-15 ml orally once a day of Senna Leaves
23 mg per cup orally once a day of Sennoside Extract Tea
8.6 mg of 2 tablets orally once a day at bedtime of Sennosides
Maximum dose: 8 tablets orally once a day
15 mg of 2 tablets orally once a day of Sennosides
or 17.2 mg of 1 tablet orally once a day
Maximum dose: 4 tablets orally once a day
20 mg of 1 tablet orally once a day of Sennosides
or 25 mg of 2 tablets orally once a day
The maximum duration of therapy is one week
Oral:
Sennosides:
Syrup (8.8 mg sennosides/5 mL):
Age: 2 to <6 years
2.5-3.75 ml orally at bedtime in divided doses
Age: 6 to <12 years
5-7.5 ml orally at bedtime in divided doses
Age: ≥12 years
10-15 ml orally at bedtime in divided doses
Tablets:
8.6 mg sennosides per tablet:
Age: 2 to <6 years
1/2 tablet orally at bedtime in divided doses
Age: 6 to <12 years:
1 tablet orally at bedtime in divided doses
Age: ≥12 years
2 tablets orally at bedtime in divided doses
15 mg sennosides-tablet:
Age: 6 to <12 years:
1 tablet orally in divided doses
Age: ≥12 years
2 tablets orally in divided doses
25 mg sennosides-tablet:
Age: 6 to <12 years:
1 tablet orally in divided doses
Age: ≥12 years
2 tablets orally in divided doses
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
it may increase the risk of adverse effects of sodium sulfate
polyethylene glycol and electrolytes
May enhance the adverse/toxic effect of polyethylene Glycol-electrolyte Solution.
may enhance the pharmacodynamic synergistic effect when combined
it may increase the risk of adverse effects of sodium sulfate
it may increase the risk of adverse effects of sodium sulfate
it may increase the risk of adverse effects of sodium sulfate
sodium picosulfate, citric acid, and magnesium oxide
it may increase the risk of adverse effects of sodium sulfate
it may increase the risk of adverse effects of sodium sulfate
it may increase the risk of adverse effects of sodium sulfate
It may enhance the risk of adverse reactions when combined with Laxatives
It may enhance the risk of adverse effects when combined with Prolactine inhibitors
when used with ipratropium, senna leaf's therapeutic efficiency may be diminished
sodium picosulfate citric acid and magnesium oxide
it may increase the risk of adverse effects of Sodium Polystyrene Sulfonate
Laxatives may increase the hypokalemic effect of dichlorphenamide
It may increase the hypokalemic effect when combined with laxatives
calcium salts: they may decrease the therapeutic effect of laxatives
calcium salts: they may decrease the therapeutic effect of laxatives
calcium salts: they may decrease the therapeutic effect of laxatives
calcium salts: they may decrease the therapeutic effect of laxatives
calcium salts: they may decrease the therapeutic effect of laxatives
antacids: they may decrease the therapeutic effect of laxative
antacids: they may decrease the therapeutic effect of laxative
antacids: they may decrease the therapeutic effect of laxative
antacids: they may decrease the therapeutic effect of laxative
antacids: they may decrease the therapeutic effect of laxative
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
bismuth subcitrate, metronidazole and tetracycline
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
may diminish the effect of each other when combined
bladderwrack may raise the laxative efficacy
Adverse drug reactions:
Frequency Not Defined
Abdominal cramps
Diarrhea
Nausea
vomiting
Pregnancy warnings:
US FDA pregnancy category: Not assigned.
Breastfeeding warnings:
The release of the drug into the human breastmilk is known
Pregnancy Categories:
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first trimester or the later trimester.
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits
Category X: Drugs listed in this category outweigh risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient Information Leaflet
Generic Name: senna
Pronounced: SEN-nah
Why do we use senna?
senna is a laxative drug which is used to treat occasional constipation and helps in bowel preparation before colonoscopy.